Où docteurs et entreprises se rencontrent

Vous avez déjà un compte ?

Nouvel utilisateur ?

post-doctoral position in preclinical imaging, radiopharmaceutical

ABG-113062 Emploi Confirmé
07/04/2023 CDD 36 Mois > 75 K€ brut annuel
Clermont Auvergne University
clermont ferrand - Auvergne-Rhône-Alpes - France
Santé, médecine humaine, vétérinaire
  • Biologie
radiopharmaceutical; preclinical imaging; mobility, PET
Recherche et Développement


UMR 1240 INSERM IMoST is based on a two teams structure entitled respectively Tatoo (Targets and Tools for imaging and therapy) and Robust (Research in functional imaging, radiopharmaceuticals and theranostic biomarkers). Team Tatoo has in charge the development and validation of innovative theranostic radiopharmaceutical tools in preclinical models, while Robust is focused on first into humans, as well as the identification of new targets and tissular biomarkers from patient biopsies.

UMR 1240 INSERM is composed of 81 permanents members and 19 phD students.

Members of IMoST have an international expertise biomarkers, as well as a recognized and long term expertise in radiopharmaceuticals and radiolabelling with a wide range of radionuclide being used (64Cu, 68Ga, 18F, 99mTc, 111In, 123I, 124I, 125I, 131I, 177Lu,…).

All investigators are backed by basic to cutting-edge equipment from chemistry to clinics :from in organic and analytical chemistry, radiochemistry (shielded hot cells), genomics and proteomics (nanostring analyzer, laser microdissection), cellular L2 culture rooms, autoradiography, and small animal imaging (Optics, SPECT-CT, PET and CT).

Equipment for in vivo small animal imaging are integrated in a “multi-scale” imaging platform called “In Vivo Imaging in Auvergne” (IVIA), labellised at national scale (IBISA).

For first into humans of radiopharmaceutical, UMR 1240 INSERM works in close interaction with the CIRMEN (Research and Innovative Center in Nuclear medicine), one of the rare structures in France dedicated for clinical transfert of radiopharmaceuticals for imaging and targeted radionuclide therapy.


Poste et missions

coordination of a preclinical research program dedicated to provide a deeper understanding of the musculoskeletal system involved in mobility in both normal and pathological situations.

Mobilité géographique :

Pas de déplacement

Télétravail :


Prise de fonction :




 Candidates should have a Ph.D in biology/physiology/preclinical imaging, or related fields, and a strong interest for

musculoskeletal system and musculoskeletal imaging,( ideally  PET/CT and SPECT/CT)

Candidates must have completed at least 3 years of postdoctoral training in a country different from the one of their PhD graduation.

Candidates currently holding a post-doctoral position in Clermont-Ferrand are not eligible.




UMR 1240 INSERM wishes to recruit a candidate to a post-doctoral fellowship program of 3 years on human mobility and health. As part of the iSITE CAP20-25 initiative – challenge 3 « personalized human mobility for a better health », the successful candidate will benefit from a EUR 300k€ package (EUR 100k€/year for 3 years). This package includes 3 years post doc salary as well as running costs for the proposed project (For more details : https://cap2025.fr/recherche/challenges-scientifiques/la-mobilite-personnalisee-comme-facteur-cle-de-la-sante/postdoctoral-research-fellowship-program) 

The UMR 1240 INSERM will assist successful high level candidates to compete for a permanent research position in a French research institution as well as for external funding (competitive grants). Resaerchers having expertise in preclinical imaging and radiopharmaceuticals are strongly encouraged to candidate.

Partager via

Vous avez déjà un compte ?

Nouvel utilisateur ?